top of page

15959335429

Highly-specialized, Swiss-German R&D firm first to market with disruptive, advanced medical inhaler for clean cannabis extracts seeks strategic funding partner

Licence(s) Held:

N/A

15959335429

Seeking strategic equity partner to fund up to ~ €1.5 million for accelerated development

  • A German R&D company focused on developing vaporizer technology as a medical device for liquid cannabis extracts aiming to solve the core issues medical inhalation today

  • The technology excels in precisely evaporating small to high dosages in a single inhalation, ensuring optimal particle size for effective lung delivery

  • Different dosages will rely on dose specific cartridges, all working on the same inhalation platform technology

  • The technology is currently patent-pending, with anticipated patent grants in Europe, USA and Australia slated in 2024 or 2025

  • ISO 13485 certification to be certified in Q2 2024

  • Experienced, industry-leading international team possessing profound knowledge in medical/pharma R&D, expertise in inhalation technologies, and a strong background in the medical cannabis regulatory field

  • The company specializes in the development and sale of customized medical inhalers, achieving sustainable profits through strategic licensing agreements with pharmaceutical customers

  • Company is seeking strategic funding partner for accelerated development and bringing the product to market

15959335429

Inquiry Form

Thanks for submitting! We have received your message and will get back to you within 24 hours. Until then, you can send an email to info@hydeadvisory.com

Contact-us-deal
bottom of page